Press Releases

Press Releases

Oct 14, 2024
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Sep 30, 2024
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Sep 23, 2024
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Sep 13, 2024
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
Aug 28, 2024
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Aug 27, 2024
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Aug 06, 2024
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
Jun 26, 2024
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Jun 10, 2024
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
Jun 04, 2024
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
Displaying 1 - 10 of 22
Media & IR Contact
Investor Relations & Media Contact

Robin Garner
Investor Relations
Contact Us

Helpful Tools